Abstract:λ lncRNA‐modulated ceRNA networks may present a promising strategy for identifying candidate biomarkers in multiple types of human cancers λ VPS9D1‐AS1 and miR‐449a may serve as a potential therapeutic target in PCa. λ The findings in this study provide a better understanding of the ceRNA network involved in the prognosis of PCa and lay a solid foundation for improving PCa diagnosis and treatment. Despite advancements in cancer research, the prognostic implications of competing endogenous RNA (ceRNA) networks in prostate cancer (PCa) remain incompletely understood. This study aimed to elucidate the prognostic relevance of ceRNA networks in PCa, utilizing a comprehensive bioinformatics approach alongside experimental validation. After searching The Cancer Genome Atlas (TCGA) database, RNA sequencing (RNA‐Seq) data were extracted to identify differentially expressed RNAs (DERs) between 491 PCa samples and 51 normal prostate tissues, following which a comprehensive bioinformatics strategy was implemented to construct a ceRNA network. An optimal prognostic signature comprising these DERs was then established and validated using TCGA data. In addition, functional validation was performed through RNA pull‐down, dual‐luciferase reporter assays, quantitative real‐time PCR, and western blot analysis conducted in PC‐3 and DU145 cell lines, thereby complementing the bioinformatics analysis. A total of 613 DERs, comprising 103 long noncoding RNAs (lncRNAs), 60 microRNAs (miRNAs), and 450 messenger RNAs (mRNAs), were identified and utilized in constructing a ceRNA network, which encompassed 23 lncRNAs, 9 miRNAs, and 52 mRNAs. An optimal prognostic signature was established, including VPS9D1 antisense RNA 1 (VPS9D1‐AS1), miR‐449a, cyclin‐dependent kinase 5 regulatory subunit 1 (CDK5R1), targeting protein for Xklp2 (TPX2), solute carrier family 7 member 11 (SLC7A11), copine7 (CPNE7), and maternal embryonic leucine zipper kinase (MELK), yielding area under the curve (AUC) values exceeding 0.8 across training, validation, and entire datasets. Our experiments results revealed an interaction between lncRNA TRHDE antisense RNA 1 (TRHDE‐AS1) and miR‐449a and that miR‐449a could target the ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5) mRNA. Knockdown of miR‐449a significantly impeded cell proliferation, G1/S transition, migration and invasion, and promoted apoptosis in PC‐3 and DU145 cells. Furthermore, knockdown of miR‐449a notably downregulated protein expression of CDK4, cyclin D1, N‐cadherin and vimentin, while upregulating protein expression of cleaved caspase‐3 and E‐cadherin. This study contributes to a deeper understanding of the prognostic‐linked ceRNA network in PCa, providing fundamental insights that could improve diagnostic and therapeutic approaches for PCa management.

Identification of novel biomarkers in prostate cancer diagnosis and prognosis

The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer.

Identification of Potential Key Genes for Pathogenesis and Prognosis in Prostate Cancer by Integrated Analysis of Gene Expression Profiles and the Cancer Genome Atlas.

Identification of Candidate Hub Genes Correlated with the Pathogenesis, Diagnosis, and Prognosis of Prostate Cancer by Integrated Bioinformatics Analysis.

Identification of Novel Biomarkers and Targets for Natural Products in Inhibiting Prostate Cancer

Identification of Pathologic and Prognostic Genes in Prostate Cancer Based on Database Mining

Diagnostic Performance of PCA3 and Hk2 in Combination with Serum PSA for Prostate Cancer.

Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis

In silico analysis of prognostic and diagnostic significance of target genes from prostate cancer cell lines derived exomicroRNAs

Four Novel Prognostic Genes Related to Prostate Cancer Identified Using Co-expression Structure Network Analysis

Novel Gene Signatures for Prostate Cancer Detection: Network Centrality-based Screening with Experimental Validation

Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer

Identification of Specific Long Non-Coding Ribonucleic Acid Signatures and Regulatory Networks in Prostate Cancer in Fine-Needle Aspiration Biopsies

Characterization and Validation of Long Noncoding RNAs As New Candidates in Prostate Cancer

Identification and validation of the TRHDE‐AS1/hsa‐miR‐449a/ADAMTS5 axis as a novel prognostic biomarker in prostate cancer

Identification of prostate cancer associated genes for diagnosis and prognosis: a modernized in silico approach

Identification of ARHGEF38, NETO2, GOLM1, and SAPCD2 Associated With Prostate Cancer Progression by Bioinformatic Analysis and Experimental Validation

Identification and validation of diagnostic and prognostic biomarkers in prostate cancer based on WGCNA

Competing Endogenous RNA and Coexpression Network Analysis for Identification of Potential Biomarkers and Therapeutics in Association with Metastasis Risk and Progression of Prostate Cancer

Discovery and Characterization of Long Intergenic Non-Coding RNAs (lincrna) Module Biomarkers in Prostate Cancer: an Integrative Analysis of RNA-Seq Data

Identification of novel biomarkers correlated with prostate cancer progression by an integrated bioinformatic analysis